Posted by & filed under Company Analysis, Financial analysis, Growth & Valuation.

Description: Valeant Pharmaceuticals just spent the year in the “make William Ackman even richer” business.

Source: NYTimes.com

Date: Nov 26, 2014

Link: http://dealbook.nytimes.com/2014/11/26/failed-allergan-deal-strains-valeants-business-model/

Questions for Discussions:

  • Summarize the events described in this takeover battle.
  • Who benefited the most?
  • Were there any ”losers”?

Leave a Reply

Your email address will not be published. Required fields are marked *